Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
broad spectrum cannabinoid formulation
- Development stage
- Unknown
- Lead developer
- My Next Health
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
The broad spectrum cannabinoid formulation is a cannabis-derived investigational drug product containing the phytocannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC). Developed through a collaboration between the University of Regina and My Next Health Inc., the formulation is designed to target the endocannabinoid system to provide neuroprotective and anti-inflammatory benefits. It is primarily being evaluated for the prevention and treatment of concussions and post-concussion syndrome in athletes participating in contact sports, as well as for pain management as a potential alternative to opioids. The development program is notably supported by funding from the National Football League (NFL) and is currently being studied in a Phase II clinical trial (NCT06204003).
- Other names
- Naturally Produced Cannabinoidscannabinoid gel capsule
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CNR2 (Cannabinoid receptor type 2)MOR (Mu opioid receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))ABCG2 (Breast cancer resistance protein)TRPV1 (Transient receptor potential cation channel subfamily V member 1)Cyp (Cyclophilin family)GPR55 (G protein-coupled receptor 55)TRPA1 (Transient receptor potential cation channel subfamily A member 1)FAAHGlycine receptor
Beyond the preview
Go deeper on broad spectrum cannabinoid formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on broad spectrum cannabinoid formulation.